Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2020 | CaboPoint: second-line cabozantinib for RCC

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the CaboPoint trial (NCT03945773). This study focuses on cabozantinib as a second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter